What does SecondWave Systems, Inc. do?
SecondWave Systems is a clinical-stage medical device company focused on developing noninvasive, wearable, and personalized ultrasound stimulation platforms. Their flagship product, the SecondWave MINI™ device, leverages proprietary low-intensity focused ultrasound technology to stimulate the spleen and offer new treatment options for patients suffering from acute and chronic inflammation disorders.
How much did they raise?
The company raised $7M in a Series A funding round. The round was led by Treo Ventures, with participation from Scientific Health Development, the University of Minnesota’s Discovery Capital, and SSBCI funds.
What are their plans for the money?
The new funds will support the next phase of clinical studies, building on the promising results of their first-in-human trial that demonstrated a reduction in rheumatoid arthritis disease activity. This investment is expected to accelerate the development and clinical validation of their innovative ultrasound-based treatment platform.
What have they achieved so far?
SecondWave Systems has already made significant progress by successfully completing its first-in-human study, which showed a reduction in rheumatoid arthritis disease activity, underscoring the potential impact of their technology on treating inflammatory diseases.
